Rubius Therapeutics Inc (NASDAQ:RUBY)
| 0.23 Delayed Data As of Feb 08 |  -0.033 / -12.55%Today’s Change | 0.14 Today|||52-Week Range 6.54 | +31.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $26.6M |
Company Description
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Foxboro, MA.
Contact Information
Rubius Therapeutics, Inc. 399 Binney Street Cambridge Massachusetts 02139 |
Employees
Shareholders
| Individual stakeholders | 50.32% |
| Mutual fund holders | 16.68% |
| Other institutional | 15.56% |
Top Executives
| Dannielle Appelhans | President, Chief Executive & Financial Officer |
| Spencer Fisk | Chief Technical Operations |
| Mark Hernon | Chief Information Officer |
| Theo Proukou | Chief People Officer & Senior Vice President |
| Greg Whitehead | Chief Quality Officer & Senior Vice President |
